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Furthermore, they show that
inflammatory cytokines activate
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ductal cells in vivo independently of
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A major goal of diabetes research is to develop stra-
tegies that replenish pancreatic insulin-producing
beta cells. One emerging strategy is to harness
pancreatic plasticity—the ability of pancreatic cells
to undergo cellular interconversions—a phenome-
non implicated in physiological stress and pancreatic
injury. Here, we investigate the effects of inflamma-
tory cytokine stress on the differentiation potential
of ductal cells in a human cell line, in mouse ductal
cells by pancreatic intraductal injection, and during
the progression of autoimmune diabetes in the non-
obese diabetic (NOD) mouse model. We find that
inflammatory cytokine insults stimulate epithelial-
to-mesenchymal transition (EMT) as well as the
endocrine program in human pancreatic ductal cells
via STAT3-dependent NGN3 activation. Further-
more, we show that inflammatory cytokines activate
ductal-to-endocrine cell reprogramming in vivo inde-
pendent of hyperglycemic stress. Together, our find-
ings provide evidence that inflammatory cytokines
direct ductal-to-endocrine cell differentiation, with
implications for beta cell regeneration.
INTRODUCTION
The ability of the pancreas to host an array of intrapancreatic
cellular conversions offers promise to the fields of regenerative
biology and diabetes research. A growing and compelling line
of evidence in rodents and humans suggests that pancreatic
cell plasticity allows the generation of insulin-producing cells
from non-beta cell sources, particularly during times of need
(e.g., beta cell loss, pancreatic injury, or metabolic stress) (Val-460 Cell Reports 15, 460–470, April 19, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://dez et al., 2015). Various groups have argued for or against
this phenomenon in an ongoing debate about the origin of the
newly formed beta cells (Dor et al., 2004; Kopp et al., 2011; Kul-
karni et al., 2004; Nir et al., 2007; Solar et al., 2009; Xiao et al.,
2013). Given its potential therapeutic applications, it is timely
to address these questions to obtain a better understanding of
the mechanisms that control pancreatic cell plasticity.
The pancreas is a highly diversified glandular organ that
houses two major cell types that contribute to the endocrine
and exocrine compartments. The former constitutes 2% of
the pancreas and consists of five hormone-secreting cells—
alpha, beta, delta, gamma (PP), and epsilon cells—that make
up the islets of Langerhans. The remainder of the pancreas is
made up of the exocrine portion and contains acinar and ductal
cells, which are responsible for digestive enzyme and bicarbon-
ate secretions. Pancreatic cell plasticity has been reported in
most of these cells, both endocrine and exocrine, using a variety
of models and experimental approaches (Valdez et al., 2015).
Furthermore, numerous studies have reported that pancreatic
cell interconversions are mediated via the emergence of
NGN3, a key endocrine progenitor transcription factor necessary
for endocrine cell specification (Rukstalis and Habener, 2009).
While there are some links between inflammatory stress
and exocrine ductal cell transdifferentiation, detailed cell and
molecular mechanisms have not been fully established. Hence,
we sought to investigate whether stress, induced specifically
by proinflammatory cytokines, tumor necrosis factor a (TNF-a),
interleukin 1b (IL-1b), and interferon g (IFN-g)—critical cytokines
implicated in the pathogenesis of both type 1 and type 2 dia-
betes—have the ability to direct the differentiation of human
andmouse pancreatic ductal cells toward the endocrine lineage.
Here, we report that inflammatory signaling induces epithelial-
to-mesenchymal transition (EMT) and the upregulation of the
endocrine progenitor marker NGN3 via STAT3 activation in the
human ductal epithelial cell line PANC-1. By performing a parallel
in vivo approach, a pancreatic intraductal injection of the samecreativecommons.org/licenses/by-nc-nd/4.0/).
cocktail of proinflammatory cytokines in C57BL/6mice, we show
that the acute inflammatory cytokine insult on pancreatic ductal
cells is sufficient to stimulate ductal-to-endocrine cell reprog-
ramming. Finally, by following the progression of autoimmune
diabetes in the non-obese diabetic (NOD) mouse model, we
demonstrate that ductal cell proliferation, as well as the emer-
gence of NGN3 and phosphorylated STAT3 (pSTAT3) expres-
sion in pancreatic ductal cells, correlates with the presence of
serum cytokine levels and pancreatic immune cell infiltration,
independent of hyperglycemic stress.
RESULTS
Inflammatory Cytokines Induce Epithelial-to-
Mesenchymal Transition in Human Ductal Cells
The human ductal epithelial cell line PANC-1, a commonly used
cell line for in vitro differentiation studies (Hardikar et al., 2003;
Lefebvre et al., 2010; Wu et al., 2010), was treated either with
a single cytokine or different combinations of the three proin-
flammatory cytokines—TNF-a, IL-1b, and IFN-g—for 24, 48, or
72 hr. The optimal dose of cytokines (Cx) used for stimulations
was finalized following dose optimization studies and is
referred to as [13] (TNF-a [50 ng/ml], IL-1b [25 ng/ml], and
IFN-g [100 ng/ml]) (Figures S1A–S1C).
To assess cytokine-induced stress, mRNA levels of iNOS and
CHOP were measured by qPCR in untreated or [13] cytokine-
treated PANC-1 cells. These analyses demonstrated an increase
in iNOS andCHOP gene expression at all time points (Figure 1A).
Furthermore, immunofluorescence analyses revealed a signifi-
cant increase in the apoptosis marker, cleaved caspase-3,
following cytokine stimulations relative to untreated controls
(Figure 1B, left, top and bottom).
An important decision progenitor cells must make is to prolif-
erate or differentiate, as many cells, including beta cell progeni-
tors (Kim et al., 2015), must temporarily defer their proliferative
abilities while undergoing differentiation (Gingold et al., 2014;
Zhu and Skoultchi, 2001). To assess proliferation, we performed
Ki67 immunostaining analyses (Figure 1B, right, top and bottom)
and assessed cell growth (Figure S1D). Cytokine treatment of
PANC-1 cells led to a significant decrease in the proliferation
marker Ki67 at 72 hr (Figure 1B, right, top and bottom) and
reduced cell numbers at all time points (Figure S1D) relative to
untreated controls. In addition, observation by bright-fieldmicro-
scopy revealed a morphological change in cytokine-treated
cells. Untreated PANC-1 cells exhibited a normal epithelial-like
morphology (Lieber et al., 1975), while cytokine-treated cells
appeared more mesenchymal-like at all time points (Figure 1C;
representative data shown for 72 hr) (Attali et al., 2007).
Since EMT is associated with the differentiation of epithelial
cells toward a pancreatic endocrine progenitor state (Rukstalis
and Habener, 2007), we assessed the levels of the ductal
cell marker carbonic anhydrase II (CA-II), the epithelial marker
E-cadherin (CDH1), and the mesenchymal marker SNAIL2 by
qPCR. These analyses demonstrated a significant decrease in
mRNA levels of the ductal cell marker CA-II and the epithelial
marker CDH1 at all time points, as well as a significant increase
in the mesenchymal marker SNAIL2 (Rukstalis and Habener,
2007) at 72 hr (Figures 1D–1F). Protein immunoblot analysesalso revealed a decrease in CDH1 and an increase in SNAIL2
in PANC-1 cells treated with cytokines at 72 hr relative to un-
treated controls (Figures 1G and 1H). Together, these data sug-
gest that proinflammatory cytokine-induced stress triggers the
loss of ductal cell identity in the human epithelial ductal cell
line PANC-1 and stimulates their differentiation from an epithelial
cell type toward a mesenchymal-like cell.
Proinflammatory Cytokines Upregulate NGN3 in Human
Ductal Cells via STAT3 Signaling
To further address the hypothesis that cytokine-induced
stress induces the differentiation of the human ductal cell line,
PANC-1, toward the endocrine cell lineage, we assessed the
expression of the endocrine progenitor marker NGN3. Following
[13] cytokine stimulation, qPCR analyses revealed an upregula-
tion of NGN3 expression at all time points in cytokine-treated
conditions relative to untreated controls (Figure 2A; dose optimi-
zations are shown in Figures S2A–S2C). These results were
corroborated at the protein level by immunofluorescence (Fig-
ures 2B and 2C). In addition, gene expression of the endocrine
markers NKX6.1 (Figures S2D–S2G) and HNF6 (Figure S2H)
were also upregulated in PANC-1 cells upon cytokine stimula-
tion. To assess the specificity of cytokine-induced endocrine
progenitor upregulation in human ductal cells, we used another
cell line of similar (endodermal) developmental origin, the human
liver cell line HepG2. Stimulation with the same cocktail of
proinflammatory cytokines did not significantly affect the
mRNA expression levels of NGN3, NKX6.1, or HNF6 relative to
untreated controls at any time point (Figures S2I–S2K).
Next, to investigate the gene expression levels of NGN3
in PANC-1 cells after cytokine removal, we divided the experi-
ment into three groups: (1) 96-hr untreated control (Ctrl), (2)
48 hr without cytokines + 48 hr with cytokines, (CxjCx+), and
(3) 48 hr with cytokines + 48 hr without cytokines (Cx+jCx).
As expected, there was a downregulation in the expression of
the stress marker iNOS gene after cytokine removal (Cx+jCx),
but, interestingly, NGN3 mRNA and protein levels, as well as
NKX6.1 and HNF6 mRNA levels, remained elevated even after
cytokine removal (Figures 2D, 2E, S2L, and S2M).
qPCR analyses of the three proinflammatory cytokines re-
vealed an autocrine upregulation of TNFa and IL-1b gene
expression as has been previously reported (Brewington et al.,
2001), but not that of IFNg (Figure 2F). These observations could,
in part, explain the persistent and elevated expression of endo-
crine genes even upon cytokine removal (Figures 2D, 2E, S2L,
and S2M). To test this, we treated PANC-1 cells with a cocktail
of specific receptor antagonists (TNF-a R [25 mM], IL-1 R
[50 mM], and IFN-g R [25 mM]) after cytokine removal and exam-
ined NGN3 protein expression by immunoblot analysis. We
found that NGN3 expression is markedly decreased in the pres-
ence of cytokine receptor antagonists (Cx+jAg) relative to the
cytokine-treated (CxjCx+) and cytokine-depleted (Cx+jCx)
conditions (Figure 2E).
Since NGN3 is a downstream effector of STAT3 (Baeyens
et al., 2006; Kaucher et al., 2012; Lemper et al., 2015) and
STAT3 has been shown to be activated by inflammatory
signaling (Ivashkiv and Donlin, 2014; Yu et al., 2009), we as-
sessed whether NGN3 upregulation in our proinflammatoryCell Reports 15, 460–470, April 19, 2016 461
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Figure 1. Epithelial-to-Mesenchymal Transition in Cytokine-Treated Human Ductal Cells
(A) qPCR analysis of iNOS and CHOP in untreated (Ctrl) or cytokine-treated (13 Cx: TNFa [50 ng/ml], IL-1b [25 ng/ml], and IFN-g [100 ng/ml]) PANC-1 cells.
(B) Representative immunofluorescence images of untreated or cytokine-treated cells for Ki67 and cleaved caspase-3 staining at 72 hr (top). The quantification of
Ki67 or cleaved caspase-3/DAPI data are shown in the bottom panels. Scale bar, 100 mM.
(C) Representative bright-field images of PANC-1 cells at 72 hr under untreated or cytokine-treated conditions. Scale bar, 100 mM.
(D–F) qPCR analysis of (D) ductal marker,CA-II; (E) epithelial marker,CDH1; and (F) mesenchymalmarker,SNAIL2, in untreated or cytokine-treated cells at 24, 48,
and 72 hr.
(G and H) Protein immunoblot analysis (G) and quantification (H) of CDH1 (E-cadherin) and SNAIL2 after 13Cx treatment at 72 hr. All qPCR data were normalized
to beta actin.
Data represent mean ± SEM. *p % 0.05 and **p % 0.005 relative to untreated controls (n = 3 for each group). All experiments were repeated at least on two
independent occasions.cytokine-treated PANC-1 cell model is mediated through STAT3
activation. To this end, we used a pSTAT3 small-molecule inhib-
itor (Stattic, Selleckchem) and assessed the levels of pSTAT3 by462 Cell Reports 15, 460–470, April 19, 2016immunoblot analyses. Our results demonstrate that [13] cyto-
kine stimulation at 72 hr induces an increase in pSTAT3 relative
to untreated and DMSO-treated controls, which is abrogated
Figure 2. NGN3 Upregulation in Human
Ductal Cells upon Inflammatory Cytokine
Stimulation
(A) qPCR analysis of NGN3 in untreated or cyto-
kine-treated (TNF-a, IL-1b, and IFN-g) PANC-1
cells at 24, 48, and 72 hr.
(B and C) Representative immunofluorescence
images (B) and quantification (C) of untreated or
cytokine-treated cells for NGN3 (red) and DAPI
(blue) at 72 hr.
(D) qPCR analysis of iNOS and NGN3 after (1)
96hrs untreated conditions (ctrl), (2) 48 hr without
cytokines + 48 hr with cytokines (CxjCx+), or (3)
48hrs with cytokines + 48 hr of cytokine removal
(Cx+jCx).
(E) Protein immunoblot analysis of NGN3 after (1)
96 hr untreated conditions, (2) 48 hr without cy-
tokines + 48 hr with cytokines (CxjCx+), (3) 48 hr
with cytokines + 48 hr of cytokine removal
(Cx+jCx), and (4) 48 hr with cytokines + 48 hr of
cytokine removal with specific cytokine receptor
antagonists (TNFa R [25 mM], IL-1 R [50 mM], and
IFN-g R [25mM]; (Cx+jAg). Beta actin was used as
a loading control.
(F) qPCR analysis of TNFa, IL-1b, and IFNg in un-
treated and [13] cytokine-treated PANC-1 cells at
48 hr. All qPCRdata were normalized to beta actin.
(G) Protein immunoblot analysis of pSTAT3, total
STAT3, and NGN3, in untreated control, DMSO-
treated control, 13 cytokine-treated (Cx), Stattic
[5 mM], or [13] cytokine + Stattic [5 mM] treatment
after 48hr.Beta actinwasusedasa loading control.
Data represent mean ± SEM. *p% 0.05 and ***p%
0.0005 (n = 3 for each group). Experiments were
repeated at least on two independent occasions.upon Stattic [5 mM] and decreased to control levels upon Cx +
Stattic [5 mM] treatment (Figure 2G). Importantly, NGN3 protein
expression is upregulated only upon [13] cytokine stimulation
relative to untreated and DMSO controls, but not when cells
are treated with Stattic [5 mM] or Cx + Stattic [5 mM] (Figure 2G).
Together, our results indicate that proinflammatory cytokines
upregulate NGN3 expression in the human ductal cell line
PANC-1, and this requires the activation of pSTAT3.
Pancreatic Intraductal Injection of Proinflammatory
Cytokines Stimulates Ductal Cell Proliferation and an
Increase in Insulin+ Ductal Cells in Mice
To explore the effects of proinflammatory cytokine stimulation
in vivo, we performed a single injection of the cocktail of cyto-
kines (TNF-a, IL-1b, and IFN-g) directly into the pancreatic
duct of 8- to 10-week-old C57BL/6mice.Weperformed these in-
jections at a [13], [23], or [103] dose and compared them to sa-
line-injected controls (Figures 3A and S3A).
Following the intraductal injections, we measured blood
glucose levels weekly for 3 weeks and injected bromodeoxyuri-
dine (BrdU) intraperitoneally in all mice at 3 days and at 5 hr prior
to sacrifice (Figures 3B and S3A). The lack of significant differ-
ences in blood glucose levels among the groups ruled out
possible effects induced by hyperglycemic stress (Figure 3B).
Three weeks post-injection, we harvested the pancreata and
performed immunohistochemistry.Immunofluorescence analyses demonstrated increased levels
of ductal cell proliferation, as measured by co-immunostaining
for BrdU and the ductal marker (DBA) at [23] and [103] con-
centrations relative to saline-injected mice (Figures 3C and
3D). Strikingly, immunostaining analyses also revealed an in-
crease in the number of insulin+ ductal cells in a dose-depen-
dent manner in cytokine-injected mice (Figures 3E–3H, S3B,
and S3C). Moreover, to investigate whether these insulin+
ductal cells displayed characteristics of true beta cells, we
co-immunostained insulin with other markers of beta cell iden-
tity: secretory granule protein, chromogranin A (Lukinius et al.,
2003), and the insulin precursor proinsulin (de la Rosa and de
Pablo, 2011). Our results revealed that the number of chromog-
ranin A/DBA (Figures 3E and 3F) and proinsulin/DBA (Figures
3G and 3H) double-positive cells significantly increased in all
cytokine injection groups relative to saline-injected controls.
In addition, we found that the majority of insulin+ ductal cells
also expressed proinsulin (Figures 3G and 3H), whereas the
number of chromogranin A+ ductal cells was higher than that
of insulin+ ductal cells in all groups (Figures 3E and 3F). Since
Chromogranin A is also expressed in the secretory granules
of other endocrine cells (Lukinius et al., 2003), our results sug-
gest that some ductal cells may adopt a non-beta endocrine
cell fate. In addition, we did not observe NGN3+ ductal cells
in these sections (data not shown), in contrast to our findings
in vitro. These findings suggest that the acute effects of a singleCell Reports 15, 460–470, April 19, 2016 463
proinflammatory cytokine injection is unlikely to be sufficient
to maintain endocrine cells in an undifferentiated state for a
prolonged period, perhaps due to a transient expression of
NGN3, in pancreatic ducts.
Ductal Cell Proliferation and Emergence of NGN3+ and
pSTAT3+ Ductal Cells Correlate with Immune Cell
Infiltration, and Not Hyperglycemia, in NOD Mice
Previous studies using the NOD mouse model have reported an
increase in pancreatic ductal cell proliferation and in the number
of insulin+ and glucagon+ ductal cells in diabetic conditions
(O’Reilly et al., 1997). Furthermore, it has been reported that cells
harvested from the ductal epithelium of NOD mice contain pro-
genitor cells capable of clustering and forming functional islets
in vitro that can be re-implanted into NODmice to restore normo-
glycemia (Ramiya et al., 2000).
Based on these reports, we sought to investigate whether
chronic pancreatic immune cell infiltration can generate NGN3+
endocrine progenitor cells in the pancreatic ducts of NOD mice
at various stages of autoimmune diabetes progression. We har-
vested the pancreata of mice at three pre-diabetic (3, 8, and
12 weeks of age) and two diabetic stages (new onset diabetes
at 1–2 weeks post-diabetes onset and established diabetes at
5–6 weeks post-diabetes onset) (Figure 4A). Blood glucose
levels were measured weekly, and mice with glucose levels
greater than 200mg/dl on two consecutive days were consid-
ered diabetic (Figure 4B). Serum levels of insulin, C-peptide,
and glucagon were also assessed (Figures S4A–S4C).
To assess serum levels of TNF-a, IL-1b, and IFN-g, we per-
formed a high-sensitivity cytokine multiplex assay and observed
that the levels of all three cytokines peaked prior to the onset of
diabetes and decreased at the established diabetes stage (Fig-
ure 4C). Levels of an eosinophil chemoattractant, Eotaxin (Gar-
cia-Zepeda et al., 1996), and cytokine, IL-6, were also highest
before the onset of diabetes (Figures S4D and S4E). Even though
the serum levels of IFN-g have previously been reported to grad-
ually increase before diabetes onset (Schloot et al., 2002), our
study has observed a decrease in serum cytokine levels after
diabetes is established (5–6 weeks post-diabetes). In addition,
we confirmed immune cell infiltration in the pancreas by H&E
staining and quantified insulitis scores. These results demon-
strate that pancreatic insulitis commences prior to the onset of
hyperglycemia and decreases at the established diabetes stage
(Figures 4D and 4D0).
We then assessed ductal cell proliferation at all stages of
diabetes progression by immunofluorescence analyses. Our
study demonstrates that ductal cell proliferation (BrdU/DBA
double-positive cells) peaks at diabetes onset and significantly
decreases when diabetes is established (Figures 4E and 4E0),
correlating with pancreatic insulitis. Interestingly, immunofluo-
rescence analyses also revealed the presence of NGN3/DBA
and pSTAT3/DBA double-positive cells in NOD mice before the
onset of hyperglycemia, correlating with the increased serum
proinflammatory cytokine levels and the development of pancre-
atic immune cell infiltration observed at pre-diabetic stages (Fig-
ures 4F, 4F0, 4G, and 4G0). Although some insulin/DBA double+
were detected in the pre-diabetic and new-onset diabetes
stages, no insulin+ ductal cells were found in the established dia-464 Cell Reports 15, 460–470, April 19, 2016betes stage despite the presence of NGN3 (Figures 4F, 4F0, and
S4F). These observations suggest that the prolonged effects
of inflammatory stress in the established diabetes stage may
maintain cells in an undifferentiated state and limit the formation
of insulin+ ductal cells.
To control for potential effects of aging in a non-NOD mouse
model, we used C57BL/6 mice at 3, 12, and 20 weeks of age.
Immunofluorescence analyses did not reveal a significant in-
crease in ductal cell proliferation. On the contrary, we observed
a significant decrease in BrdU/DBA double-positive cells, sug-
gesting an attenuation in ductal cell proliferation with age (Fig-
ures S4G and S4H). Moreover, and as expected, H&E staining
did not reveal insulitis in these mice, and we did not detect
NGN3/DBA or pSTAT3/DBA double-positive cells at any of the
time points studied (data not shown). Together, our data suggest
that ductal cell proliferation and the emergence of NGN3+ or
pSTAT3+ ductal cells are driven by insulitis and elevated cytokine
levels, but not hyperglycemia or age.
DISCUSSION
Diabetes is associated with reduced pancreatic beta cell mass
that has prompted major efforts toward the development of
novel beta cell regeneration strategies. Under diverse states
of physiological stress (high nutrient/caloric intake or inflamma-
tion) (Ninov et al., 2013), pathophysiological insults (insulin
resistance) (Mezza et al., 2014), or severe pancreatic injury (par-
tial pancreatectomy or duct ligation) (Li et al., 2010; Walker
et al., 1992), several studies demonstrate the ability of the
pancreas to undergo cellular interconversions. For example,
metabolic stress in islets of several type 2 diabetes (T2D)
mouse models has been shown to activate NGN3 in pancreatic
beta cells, prompting their regression into an endocrine progen-
itor stage (Talchai et al., 2012). Relief from hyperglycemic stress
via insulin therapy allows these insulin/NGN3+ progenitor
cells to redifferentiate into functional insulin+ cells (Wang
et al., 2014). In addition, it has been demonstrated that stress
encountered during human islet isolation stimulates inflamma-
tory signaling that leads to beta cell dedifferentiation via the
emergence of progenitor-specific transcription factors (Negi
et al., 2012).
Due to its profusion, exocrine tissue is a strong endogenous
candidate for beta cell neogenesis. Previous studies have shown
that inflammation can induce exocrine acinar cells to give rise to
progenitor cells in cases of autoimmune or chronic pancreatitis
in humans (Ko et al., 2013). More recently, Baeyens et al.
(2014) used diabetic mice in an elegant study to demonstrate
that acinar cells are capable of restoring a glucose-responsive,
functional beta cell mass upon a transient cytokine (EGF and
CNTF) exposure through the activation of STAT3 and NGN3
(Baeyens et al., 2014).
The exocrine ductal cell is another highly studied pancreatic
cell type that has been shown to exhibit cellular plasticity. Using
mice, various groups have reported that pancreatic ductal cells
can serve as a source of NGN3+ endocrine progenitors following
stressors, such as pancreatic injury by duct ligation (Bonner-
Weir et al., 1993), partial pancreatectomy (Walker et al., 1992),
or targeted beta cell destruction via constitutive IFN-g
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Figure 4. Ductal Cell Proliferation and Emergence of NGN3+ and pSTAT3+ Ductal Cells Correlate with Immune Cell Infiltration, and Not
Hyperglycemia, in NOD Mice
(A) Experimental design using female NOD mouse model of autoimmune diabetes.
(B) Blood glucose levels of NOD mice throughout diabetes progression.
(C) Serum levels of TNF-a, IL-1b, and IFN-g cytokines measured by Luminex multiplex assay. Asterisk (*) applies to the three cytokines.
(D and D0) Representative bright-field images (D) and quantification (D0) of islet insulitis at different time points of diabetes progression. Scale bar, 100 mM.
(E and E0) Representative immunofluorescence images (E) and quantification (E0) of BrdU+ (red) ductal (DBA+ green) cells in NOD mice throughout diabetes
progression. Nuclei were stained with DAPI (blue). Scale bar, 100 mM.
(F and F0) Representative immunofluorescence images (F) and quantification (F0 ) of NGN3+ (red) ductal (DBA; green) cells in NOD mice throughout diabetes
progression. Scale bar, 20 mM.
(G and G0) Representative immunofluorescence images (G) and quantification (G0) of pSTAT3+ (red) ductal (DBA; green) cells in NOD mice throughout diabetes
progression. Scale bar, 20 mM.
Data represent mean ± SEM. *p% 0.05 and **p% 0.005 (n = 4–9 for each group).expression (Gu et al., 1995a, 1995b; Gu and Sarvetnick, 1993).
Using human primary ductal cells, Seung Kim’s group demon-
strated that the transgenic expression of NGN3 along with otherFigure 3. Pancreatic Intraductal Injection of Proinflammatory Cytokin
Ductal Cells in Mice
(A) Representative image of mouse undergoing pancreatic intraductal injection su
the pancreatic duct of C57BL/6 (B6) mice aged 8–10 weeks were performed usin
IL-1b, and IFN-g) at [13], [23], and [103] doses. 3 weeks after injection, the panc
weight (BW)] BrdU 3 days and 5 hr before harvesting pancreas.
(B) Blood glucose levels of saline, [13], [23], or [103] cytokine-injected mice.
(C and D) Representative immunofluorescence images (C) and quantification (D) o
DBA (green) at 3 weeks post-injection (blue indicates DAPI staining). Scale bar, 1
(E and F) Representative immunofluorescence images (E) and quantification (F) of
(CHGA) (red), insulin (blue), and DBA (green) at 3 weeks post-injection. Scale ba
(G and H) Immunofluorescence images (G) and quantification (H) of saline-injecte
and DBA (green) at 3 weeks post-injection. Scale bar, 100 mM.
Data represent mean ± SEM. *p% 0.05, ## and **p% 0.005, and ***p% 0.0005
466 Cell Reports 15, 460–470, April 19, 2016critical endocrine factors is important for their conversion into
glucose-responsive, insulin-secreting endocrine cells (Lee
et al., 2013). In addition, some studies have shown that humanses Stimulates Ductal Cell Proliferation and an Increase in Insulin+
rgery. Evans blue dye shows inflated pancreas. Intrapancreatic injections into
g saline or a single injection of the cocktail of inflammatory cytokines (TNF-a,
reas was harvested. Mice were injected intraperitoneally with [100 mg/kg body
f saline-injected, [13], [23], or [103] cytokine-injected mice for BrdU (red) and
00 mM.
saline-injected, [13], [23], or [103] cytokine-injected mice for chromogranin A
r, 100 mM.
d, [13], [23], or [103] cytokine-injected mice for proinsulin (red), insulin (blue),
relative to respective saline-injected controls. (n = 4–6 for each group).
that undergo physiological stress in the form of insulin resistance
exhibit an increase in insulin+ ductal cells relative to control sub-
jects (Mezza et al., 2014).
Based on these studies, the aim of our work was to investi-
gate whether stress caused specifically by proinflammatory
cytokine insults could induce ductal-to-endocrine cell differenti-
ation. In this report, we demonstrate that a cocktail of proinflam-
matory cytokines (TNF-a, IL-1b, and IFN-g) can activate the
endocrine program in exocrine ductal cells. While previous
studies have reported the effect of chronic inflammatory cyto-
kine stimulation on mouse ductal cells in vivo (Gu et al., 1997,
1995a, 1995b), our study is unique for several reasons. First,
we report that acute proinflammatory cytokine stimulation via
pancreatic intraductal injection is able to induce an increase in
ductal cell proliferation in vivo as measured by BrdU incorpora-
tion. The decrease, rather than increase, in ductal cell prolifera-
tion observed in vitro could be potentially due to the direct and
sustained exposure of the target cells to inflammatory cytokines
that may not be observed in vivo. Second, the significant in-
crease in insulin+ ductal cells in our intraductal injection model
suggests that an acute insult of proinflammatory cytokines is
sufficient to activate ductal-to-endocrine cell reprogramming.
Third, the co-expression of insulin with proinsulin and chromog-
ranin A in ductal cells indicates that they possess characteris-
tics of true beta cells.
By following the progression of diabetes in a chronic model
of autoimmune diabetes, the NOD mouse, we observed that
ductal cell proliferation and the emergence of NGN3+ and
pSTAT3+ ductal cells correlate with the presence of serum
cytokine levels and pancreatic insulitis, which begin prior to
the onset of diabetes. Together, our intraductal injection and
NOD mouse diabetes progression studies highlight the impor-
tance and specificity of proinflammatory cytokines in this phe-
nomenon and, importantly, rule out potential contributions of
hyperglycemic stress. Indeed, the detrimental effects of proin-
flammatory cytokines on beta cells and the pathogenesis of
diabetes have been widely documented (Kikodze et al., 2013;
Rabinovitch and Suarez-Pinzon, 2003). However, immune
cell-derived inflammatory cytokines have also been reported
to stimulate beta cell proliferation in mice (Dirice et al., 2014;
Dirice and Kulkarni, 2016). In addition, the Joslin Medalist
Study, which consists of patients who have had autoimmune
diabetes for at least 50 years, has also reported the presence
of scattered insulin+ cells within the pancreatic exocrine tissue
of all subjects after postmortem analyses (Keenan et al., 2010).
One possible explanation for these findings is that inflammatory
signaling activates beta cell neogenesis from both beta and
non-beta cell sources.
Finally, our in vitro cytokine stimulation model provides a
mechanistic insight into cytokine-induced endocrine activation.
As previously demonstrated, the transgenic expression of
key endocrine transcription factor NGN3, via adenovirus admin-
istration, is critical for the generation and expansion of insulin-
secreting beta cells from human primary ductal cells (Lee
et al., 2013). Here, we demonstrate that proinflammatory cyto-
kines can induce the expression of NGN3. While NGN3 expres-
sion has been shown to be mediated through STAT3 activation
in vitro (Baeyens et al., 2006; Kaucher et al., 2012; Lemper et al.,2015) and in vivo (Baeyens et al., 2014) using rodent acinar
cells, our study now highlights the relevance of STAT3 and
NGN3 in the context of a human ductal cell line, in vitro, and
throughout the progression of diabetes in mouse ductal cells,
in vivo.
The field of pancreatic plasticity is a dynamic and timely area
of investigation that has been the focus of intense examination in
recent years (Valdez et al., 2015). In this study, we have investi-
gated the effect(s) of proinflammatory cytokine-induced stress
on the differentiation potential of human and mouse ductal
cells. Since TNF-a, IL-1b, and IFN-g are three of the most critical
proinflammatory cytokines implicated in the pathogenesis of
type 1 and 2 diabetes (Al-Shukaili et al., 2013; Spranger et al.,
2003; Wang et al., 2010), our study now provides some mecha-
nistic insights into a naturally occurring phenomenon. These
findings warrant further investigation into the field of cytokine-
driven exocrine ductal cell reprogramming, an area that holds
translational relevance for the fields of diabetes and pancreatic
regenerative medicine.
EXPERIMENTAL PROCEDURES
Cell Culture and In Vitro Stimulations
The human pancreatic ductal epithelial carcinoma cell line PANC-1 was
maintained in DMEM supplemented with 10% fetal bovine serum (FBS). Cyto-
kine stimulations were carried out using this medium. For all experiments,
PANC-1 cells were plated at 1 3 106 cells/well of a 12-well plate, and each
condition was carried out in triplicate. All experiments were performed a
minimum of two times.
Cytokine Stimulations
Cells were exposed to individual or combinations of TNF-a, IL-1b, and IFN-g
in dose-response and time-course experiments. TNF-a [50 ng/ml], IL-1b
[25 ng/ml], and IFN-g [100 ng/ml] corresponds to [13] concentration.
Cytokine Receptor Antagonist Stimulations
Human recombinant interleukin-1 receptor antagonist (Creative Biomart,
catalog no. IL1RN-05H), concentration [50 mm]; human recombinant IFN-g re-
ceptor antagonist (Sigma-Aldrich, catalog no. 15152), concentration [25 mM],
and human TNF-a receptor antagonist (Santa Cruz Biotechnology, catalog
no. R-7050), concentration [25 mM], were used. Cells were treated with a cock-
tail of these cytokine receptor antagonists for 48 hr.
Stattic Stimulations
pSTAT3 inhibitor Stattic (Selleckchem, catalog no. S7024) was used at a con-
centration of 5 mM for 48 hr.
Immunofluorescence Studies
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 20 min at room temperature,
blocked with 5% donkey serum in PBS Triton X-100 (0.1%) for 1 hr at room
temperature, and stained with primary antibodies (Table S1) and appropriate
secondary antibodies. Nuclei were stained with DAPI. At least 1,000 cells
were counted per well or animal.
Immunohistochemistry
Pancreases were harvested, fixed with 4% paraformaldehyde, and embedded
in paraffin. Sections were stained using primary antibodies (Table S1) and
appropriate secondary antibodies. Nuclei were stained with DAPI. At least
1,000 cells were counted per well or animal.
qPCR
Total RNA was isolated using TRIzol (Invitrogen) according to the manufac-
turer’s recommendations followed by cDNA synthesis using standard RT-
PCR protocols. Approximately 25 ng cDNA template was mixed with 23
Sybr Green PCR Master Mix (Bio-Rad) and diluted to 13 with 100 nM primers
(Table S2) and dH2O.Cell Reports 15, 460–470, April 19, 2016 467
Immunoblot Analyses
Methods for immunoblot analyses have been described previously (Bhatt
et al., 2015).
BrdU Administration
Intraperitoneal injections of BrdU were performed in all mice 3 days and 5 hr
prior to sacrifice at a concentration of [100 mg/kg body weight] (El Ouaamari
et al., 2013).
Pancreatic Intraductal Injections
For this experiment, 8- to 10-week-old male C57BL/6 mice were anesthetized
with Avertin (240 mg/kg intraperitoneally). An incision of 3 cm was performed
through the center of the abdomen. The duodenum was then exposed and
the common bile duct was clamped near the liver. The intraductal injection
was performed using a 28G1/2 U-100 insulin syringe into the pancreatic
duct from the duodenum through the ampulla of Vater. The needle was
clamped, and 150 ml saline or a single dose of a cocktail of proinflammatory
cytokines ([13] = TNF-a [50 ng/ml], IL-1b [25 ng/ml], and IFN-g [100 ng/ml],
n = 3; [23] = TNF-a [100 ng/ml], IL-1b [50 ng/ml], and IFN-g [200 ng/ml],
n = 6; and [103] = TNF-a [500 ng/ml], IL-1b [250 ng/ml], and IFN-g
[1,000 ng/ml], n = 4) or saline injections (n = 5) were administered. After clamp
removal, the wound on the ampulla was sealed with 3M Vetbond Tissue
Adhesive (3M Animal Care). The abdominal muscle layer was closed with in-
terrupted suture, and the overlying skin was sutured using Needle Dafilon and
Polyamide Monofilament (B. Braun). Blood glucose levels were measured
once a week in the morning for 3 weeks. Pancreata were harvested 3 weeks
post-injection.
NOD Mouse Diabetes Progression Studies
Female NOD mice were purchased from The Jackson Laboratory and main-
tained in a pathogen–free animal facility at the Joslin Diabetes Center. Dia-
betes was tracked by measuring their morning blood glucose levels using a
Contour blood glucose meter (Bayer) once a week every week. Mice were
considered diabetic after two consecutive days of blood glucose levels being
greater than 200 mg/dl (Dirice et al., 2014). A total four to nine mice per group
were used and divided into five groups: 3 weeks (n = 5), 8 weeks (n = 5), and
12 weeks of age (n = 4), new onset diabetes (1–2 weeks after onset; n = 9),
and established diabetes (5–6 weeks after onset; n = 8). The pancreases of
these animals were harvested and sectioned for immunohistochemical ana-
lyses (Dirice et al., 2014).
Insulitis Scores
Pancreatic sections of NODmice were stained with H&E were ranked for insu-
litis using the following parameters: 0 = normal islet morphology with no insu-
litis, 1 = peri-insulitis, 2 = insulitis, and 3 = islet remnant, as reported previously
(Dirice et al., 2014).
Serum Cytokine Measurements Using Multiplex Assay
We collected blood samples from heart puncture of all NODmice and obtained
serum. Samples were stored at 70C until analysis. Serum cytokine levels
were measured by Luminex bead-based multiplex assay using a dual-laser
Luminex-100 instrument (Millipore) by the Joslin Diabetes Center Assay Core.
Statistical Analyses
Data are expressed as mean ± SEM, and a two-tailed Student’s t test or
ANOVA was used to confirm significance at p% 0.05.
Study Approval
All animal experiments were conducted after approval by the Institutional
Animal Care and Use Committee (IACUC) of the Joslin Diabetes Center in
accordance with National Institutes of Health (NIH) guidelines.
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